Increased gut permeability in Crohn's disease: is TNF the link?
作者信息
Gibson P R
机构信息
Department of Gastroenterology and Monash University Department of Medicine, Box Hill Hospital, Box Hill, Victoria 3128, Australia.
出版信息
Gut. 2004 Dec;53(12):1724-5. doi: 10.1136/gut.2004.047092.
Abstract
摘要
相似文献
1
Increased gut permeability in Crohn's disease: is TNF the link?
Gut. 2004 Dec;53(12):1724-5. doi: 10.1136/gut.2004.047092.
2
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
Am J Gastroenterol. 2002 Aug;97(8):2000-4. doi: 10.1111/j.1572-0241.2002.05914.x.
3
Intestinal permeability in Crohn's disease.
Acta Gastroenterol Belg. 1996 Jan-Mar;59(1):15-9.
4
Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha.
Gut. 2004 Dec;53(12):1817-24. doi: 10.1136/gut.2004.041426.
5
Increased gastric and intestinal permeability in patients with Crohn's disease.
Am J Gastroenterol. 1997 Oct;92(10):1891-6.
6
Abnormal intestinal permeability in Crohn's disease. A possible pathogenic factor.
Scand J Gastroenterol. 1990 Apr;25(4):321-8. doi: 10.3109/00365529009095493.
7
Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?
Am J Gastroenterol. 2002 Aug;97(8):1867-8. doi: 10.1111/j.1572-0241.2002.05895.x.
8
Intestinal permeability in patients with Crohn's disease and their relatives.
Dig Liver Dis. 2001 Nov;33(8):649-51. doi: 10.1016/s1590-8658(01)80038-4.
9
Intestinal epithelial barrier dysfunction in Crohn's disease.
Proc Soc Exp Biol Med. 1997 Apr;214(4):318-27. doi: 10.3181/00379727-214-44099.
10
[Detection of increased permeability of the intestinal mucosa in chronic inflammatory bowel diseases].
Z Gastroenterol Verh. 1989 Jul;24:40-4.
引用本文的文献
1
The Colonic Vitamin D Receptor and Inflammatory Bowel Disease: No Correlation to Histologic or Endoscopic Inflammation.
APMIS. 2025 Jan;133(1):e70000. doi: 10.1111/apm.70000.
2
A Comparative Study on the Effects of Mesenchymal Stem Cells and Their Conditioned Medium on Caco-2 Cells as an In Vitro Model for Inflammatory Bowel Disease.
Int J Cell Biol. 2024 Oct 21;2024:1022338. doi: 10.1155/2024/1022338. eCollection 2024.
3
The Bidirectional Effects of Periodontal Disease and Oral Dysbiosis on Gut Inflammation in Inflammatory Bowel Disease.
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjae162.
4
Effect of Organic, Nano, and Inorganic Zinc Sources on Growth Performance, Antioxidant Function, and Intestinal Health of Young Broilers.
Biol Trace Elem Res. 2025 May;203(5):2776-2786. doi: 10.1007/s12011-024-04341-y. Epub 2024 Aug 10.
5
The manganese transporter SLC39A8 links alkaline ceramidase 1 to inflammatory bowel disease.
Nat Commun. 2024 Jun 5;15(1):4775. doi: 10.1038/s41467-024-49049-8.
6
Cucurbitacin E Alleviates Colonic Barrier Function Impairment and Inflammation Response and Improves Microbial Composition on Experimental Colitis Models.
J Inflamm Res. 2024 May 6;17:2745-2756. doi: 10.2147/JIR.S456353. eCollection 2024.
7
Huangshui Polysaccharide Exerts Intestinal Barrier Protective Effects through the TLR4/MyD88/NF-B and MAPK Signaling Pathways in Caco-2 Cells.
Foods. 2023 Jan 18;12(3):450. doi: 10.3390/foods12030450.
8
Lactoferrin Alleviates Lipopolysaccharide-Induced Infantile Intestinal Immune Barrier Damage by Regulating an ELAVL1-Related Signaling Pathway.
Int J Mol Sci. 2022 Nov 8;23(22):13719. doi: 10.3390/ijms232213719.
9
[The role of the response to DNA damage in granulomatous diseases].
Z Rheumatol. 2022 Dec;81(10):881-887. doi: 10.1007/s00393-022-01260-y. Epub 2022 Aug 25.
10
Barrier Perturbation in Porcine Peyer's Patches by Tumor Necrosis Factor is Associated With a Dysregulation of Claudins.
Front Physiol. 2022 May 30;13:889552. doi: 10.3389/fphys.2022.889552. eCollection 2022.
本文引用的文献
1
Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha.
Gut. 2004 Dec;53(12):1817-24. doi: 10.1136/gut.2004.041426.
2
Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells.
J Pharm Sci. 2004 Jun;93(6):1524-36. doi: 10.1002/jps.20072.
3
Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
Gut. 2004 Jan;53(1):70-7. doi: 10.1136/gut.53.1.70.
4
Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms.
J Immunol. 2003 Dec 1;171(11):6164-72. doi: 10.4049/jimmunol.171.11.6164.
5
Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives?
Gastroenterology. 2003 Jun;124(7):1728-37. doi: 10.1016/s0016-5085(03)00383-4.
6
Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?
Gut. 2003 May;52(5):759-66. doi: 10.1136/gut.52.5.759.
7
Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate.
Gut. 2003 Feb;52(2):224-30. doi: 10.1136/gut.52.2.224.
8
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
Am J Gastroenterol. 2002 Aug;97(8):2000-4. doi: 10.1111/j.1572-0241.2002.05914.x.
9
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Lancet. 2002 May 4;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4.
10
Intestinal permeability in Crohn's disease patients and their first degree relatives.
Dig Liver Dis. 2001 Nov;33(8):680-5. doi: 10.1016/s1590-8658(01)80045-1.
Zotero 插件